tropicamide

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

About Ask DrugCentral

Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.

General architecture

Ask a questionThe browser sends your question to the same-origin Django chat API.
Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.

Using the assistant

Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.

Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.

Property	Description	Value
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,JAK1,JAK2,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MARK4,NTRK2,PDK2,PDK4,PIK3CB,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK	38
kinase-selectivity-class	AXL,BRAF,CDK9,ERBB2,GRK2,MAP2K6	6
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic anterior segment syndrome	213.84	41.42	39	2386	2211	90623811
Macular oedema	133.25	41.42	30	2395	4879	90621143
Visual acuity reduced	131.40	41.42	41	2384	23369	90602653
Eye inflammation	119.24	41.42	30	2395	7821	90618201
Endophthalmitis	112.97	41.42	26	2399	4659	90621363
Monocytosis	112.56	41.42	20	2405	974	90625048
Vision blurred	109.40	41.42	55	2370	110238	90515784
Cataract nuclear	104.14	41.42	19	2406	1075	90624947
Retinal haemorrhage	102.49	41.42	25	2400	5739	90620283
Eye pain	98.84	41.42	39	2386	44129	90581893
Vitreous floaters	95.79	41.42	25	2400	7524	90618498
Corneal oedema	93.66	41.42	19	2406	1882	90624140
Ulcerative keratitis	93.13	41.42	21	2404	3432	90622590
Conjunctival hyperaemia	89.43	41.42	20	2405	3149	90622873
Exposure to SARS-CoV-2	88.84	41.42	19	2406	2433	90623589
Cystoid macular oedema	80.22	41.42	17	2408	2083	90623939
SARS-CoV-2 test positive	64.52	41.42	20	2405	11108	90614914
Ocular hyperaemia	62.36	41.42	26	2399	33772	90592250
Visual impairment	58.36	41.42	39	2386	132326	90493696
Therapeutic product effect prolonged	58.09	41.42	10	2415	404	90625618
Hypopyon	56.25	41.42	11	2414	903	90625119
Necrotising colitis	52.07	41.42	11	2414	1327	90624695
Choroidal neovascularisation	51.48	41.42	9	2416	398	90625624
Metamorphopsia	51.13	41.42	11	2414	1446	90624576
Vitreous detachment	50.97	41.42	12	2413	2366	90623656
Intraocular pressure increased	50.78	41.42	15	2410	7078	90618944
Detachment of retinal pigment epithelium	49.54	41.42	9	2416	496	90625526
Retinal disorder	48.11	41.42	11	2414	1908	90624114
Floppy iris syndrome	46.71	41.42	7	2418	115	90625907
Cataract	46.31	41.42	27	2398	72065	90553957
Anterior chamber cell	46.16	41.42	9	2416	727	90625295
Anterior chamber fibrin	45.95	41.42	7	2418	129	90625893
Macular fibrosis	44.90	41.42	8	2417	395	90625627
Vitritis	44.51	41.42	10	2415	1604	90624418
Conjunctival ulcer	44.46	41.42	6	2419	44	90625978
Multiple use of single-use product	43.30	41.42	10	2415	1813	90624209
Periumbilical abscess	42.36	41.42	7	2418	220	90625802
Catheter site abscess	41.55	41.42	7	2418	248	90625774

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic anterior segment syndrome	180.87	38.79	33	1508	1383	42618411
Visual acuity reduced	122.74	38.79	39	1502	17511	42602283
Vitreous floaters	102.77	38.79	25	1516	4205	42615589
Blindness	74.50	38.79	27	1514	17951	42601843
Vision blurred	74.40	38.79	37	1504	53662	42566132
Floppy iris syndrome	57.54	38.79	10	1531	314	42619480
Eye pain	57.44	38.79	22	1519	17008	42602786
Endophthalmitis	53.32	38.79	15	1526	4418	42615376
Corneal oedema	52.52	38.79	12	1529	1536	42618258
Retinal haemorrhage	49.41	38.79	15	1526	5755	42614039
Anterior chamber cell	47.53	38.79	9	1532	459	42619335
Visual impairment	46.11	38.79	25	1516	43088	42576706
Cataract	45.03	38.79	22	1519	30582	42589212
Cataract nuclear	42.75	38.79	9	1532	788	42619006
Macular oedema	42.57	38.79	12	1529	3557	42616237

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic anterior segment syndrome	386.46	33.17	70	3270	3384	110582575
Visual acuity reduced	201.38	33.17	63	3277	32110	110553849
Endophthalmitis	133.82	33.17	34	3306	8153	110577806
Corneal oedema	131.18	33.17	28	3312	3145	110582814
Eye inflammation	129.99	33.17	34	3306	9137	110576822
Vision blurred	113.96	33.17	62	3278	128960	110456999
Eye pain	102.70	33.17	43	3297	50056	110535903
Blindness	101.54	33.17	39	3301	36320	110549639
Monocytosis	98.95	33.17	20	3320	1720	110584239
Vitreous floaters	97.14	33.17	27	3313	9107	110576852
Macular oedema	94.75	33.17	25	3315	6941	110579018
Anterior chamber cell	93.52	33.17	18	3322	1203	110584756
Ulcerative keratitis	88.86	33.17	22	3318	4744	110581215
Exposure to SARS-CoV-2	83.23	33.17	19	3321	2900	110583059
Retinal haemorrhage	78.20	33.17	23	3317	9478	110576481
Intraocular pressure increased	70.89	33.17	22	3318	10854	110575105
Cataract nuclear	67.25	33.17	14	3326	1392	110584567
Conjunctival hyperaemia	65.51	33.17	18	3322	5813	110580146
Vitritis	63.60	33.17	15	3325	2638	110583321
Cataract	61.35	33.17	35	3305	79450	110506509
Hypopyon	61.17	33.17	13	3327	1427	110584532
Visual impairment	60.41	33.17	42	3298	134386	110451573
Retinal disorder	59.97	33.17	14	3326	2356	110583603
Anterior chamber fibrin	54.77	33.17	9	3331	241	110585718
SARS-CoV-2 test positive	53.89	33.17	20	3320	16915	110569044
Cystoid macular oedema	52.57	33.17	13	3327	2787	110583172
Angle closure glaucoma	49.69	33.17	13	3327	3486	110582473
Choroidal neovascularisation	47.54	33.17	9	3331	550	110585409
Multiple use of single-use product	45.49	33.17	10	3330	1286	110584673
Macular fibrosis	45.21	33.17	9	3331	715	110585244
Eye disorder	43.56	33.17	20	3320	28886	110557073
Ocular hyperaemia	43.49	33.17	22	3318	39264	110546695
Vitreal cells	42.98	33.17	7	3333	177	110585782
Detachment of retinal pigment epithelium	42.27	33.17	9	3331	996	110584963
Ophthalmological examination abnormal	41.98	33.17	6	3334	61	110585898
Catheter site abscess	40.10	33.17	7	3333	271	110585688
Periumbilical abscess	39.16	33.17	7	3333	311	110585648
Uveitis	39.04	33.17	17	3323	21693	110564266
Floppy iris syndrome	38.41	33.17	7	3333	347	110585612
Vitreous detachment	38.32	33.17	10	3330	2655	110583304
Metamorphopsia	37.92	33.17	9	3331	1624	110584335
Eye irritation	37.81	33.17	19	3321	33433	110552526
Vitreous haemorrhage	37.20	33.17	11	3329	4609	110581350
Retinal scar	36.29	33.17	7	3333	472	110585487
Corneal opacity	34.89	33.17	8	3332	1243	110584716
Corneal disorder	33.78	33.17	9	3331	2588	110583371
Retinal aneurysm	33.49	33.17	6	3334	270	110585689
Therapeutic product effect prolonged	33.47	33.17	7	3333	711	110585248

Source	Code	Description
ATC	S01FA06	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics
ATC	S01FA56	SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Anticholinergics
FDA MoA	N0000175370	Cholinergic Antagonists
FDA EPC	N0000175574	Anticholinergic
MeSH PA	D009184	Mydriatics
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:66981	ophthalmology drug

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

tropicamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products:

Disease	Relation	SNOMED_ID	DOID
Dilated pupil	indication	37125009
Cycloplegia	indication	68158006	DOID:10033
Perioperative Mydriasis	indication
Ocular hypertension	contraindication	4210003	DOID:9282
Hyperthyroidism	contraindication	34486009	DOID:7998
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Diabetes mellitus	contraindication	73211009	DOID:9351
Open-angle glaucoma	contraindication	84494001	DOID:1067
Shallow anterior chamber of eye	contraindication	246986004
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Myocardial ischemia	contraindication	414795007	DOID:3393
Primary Closed Angle Glaucoma	contraindication

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2.5%;1%	MYDCOMBI	EYENOVIA	N215352	May 5, 2023	DISCN	SPRAY, METERED	OPHTHALMIC	10839960	July 15, 2031	METHOD OF ADMINISTERING AN EFFECTIVE DOSE OF TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE TO AN EYE
2.5%;1%	MYDCOMBI	EYENOVIA	N215352	May 5, 2023	DISCN	SPRAY, METERED	OPHTHALMIC	11398306	July 15, 2031	METHOD OF ADMINISTERING AN EFFECTIVE DOSE OF TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE TO AN EYE
2.5%;1%	MYDCOMBI	EYENOVIA	N215352	May 5, 2023	DISCN	SPRAY, METERED	OPHTHALMIC	11839487	July 15, 2031	METHOD OF ADMINISTERING AN EFFECTIVE DOSE OF TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE TO AN EYE

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN	ANTAGONIST	Ki	7.52	DRUG MATRIX	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.43	DRUG MATRIX
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		Ki	7.17	DRUG MATRIX
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	7.19	DRUG MATRIX
Cytochrome P450 2C9	Enzyme	P11712	CP2C9_HUMAN		IC50	6	DRUG MATRIX
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	6	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	8.46	PDSP

ID	Source
4018592	VUID
N0000146908	NUI
D00397	KEGG_DRUG
4018592	VANDF
C0041190	UMLSCUI
CHEBI:9757	CHEBI
CHEMBL1200604	ChEMBL_ID
DB00809	DRUGBANK_ID
D014331	MESH_DESCRIPTOR_UI
5593	PUBCHEM_CID
7319	IUPHAR_LIGAND_ID
1059	INN_ID
N0A3Z5XTC6	UNII
10869	RXNORM
1997	MMSL
3084	MMSL
5645	MMSL
001726	NDDF
387526001	SNOMEDCT_US
9190005	SNOMEDCT_US
N0A3Z5XTC6	INXIGHT DRUGS

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Mydriacyl	HUMAN PRESCRIPTION DRUG LABEL	1	0065-0355	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	19 sections
Mydriacyl	HUMAN PRESCRIPTION DRUG LABEL	1	0998-0355	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	19 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	17478-101	SOLUTION/ DROPS	5 mg	OPHTHALMIC	ANDA	18 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	17478-102	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	18 sections
Paremyd	HUMAN PRESCRIPTION DRUG LABEL	2	17478-704	SOLUTION	2.50 mg	OPHTHALMIC	NDA	21 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	24208-585	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	17 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	24208-590	SOLUTION/ DROPS	5 mg	OPHTHALMIC	ANDA	17 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	61314-354	SOLUTION/ DROPS	5 mg	OPHTHALMIC	ANDA	19 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	61314-355	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	11 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	70069-121	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	16 sections
Mydriatic-4	HUMAN PRESCRIPTION DRUG LABEL	4	71384-632	SOLUTION/ DROPS	10 mg	OPHTHALMIC	unapproved drug other	2 sections
MYDCOMBI	HUMAN PRESCRIPTION DRUG LABEL	2	81046-0111	SPRAY, METERED	0.08 mg	OPHTHALMIC	NDA	24 sections
Tropicamide	HUMAN PRESCRIPTION DRUG LABEL	1	85766-040	SOLUTION/ DROPS	10 mg	OPHTHALMIC	ANDA	16 sections